Expert Interview
Discussing the Phase 3 results from Ocular Therapeutix on AXPAXLI (OTX-TKI) for the treatment of wet age-related macular degeneration (wAMD)
Ticker(s): OCUL, REGN, RHHBY, EYPTInstitution: Tyler Retinal Consultants
- Vitreoretinal Surgeon and Director of Clinical Research at Tyler Retinal Consultants
- Manages 20 patients a week with wAMD
- Previous investigator on the SOL clinical trials for Axpaxli; clinical focus on the medical and surgical treatment of diseases affecting the retina, vitreous and macula
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
